Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Methotrexate Consolidation Therapy for BCR-ABL-Negative ALL
NCT00131027Phase 3Unknown
- Sponsor
- Japan Adult Leukemia Study Group
- Start
- Sep 2002
- Primary completion
- Mar 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of methotrexate in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Japan Adult Leukemia Study Group. Primary endpoint: Disease-free survival at 3 years. Status: unknown.
02
Drugs
methotrexate
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00131027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00131027.